In summary, DABIL‐4 is a promising therapeutic that demonstrates both direct killing of IL‐4R‐positive tumor cells combined with the depletion of IL‐4R‐bearing immunosuppressive cells such as MDSCs and TAMs. The gene discussed is IL4R; the disease is neoplasm.